A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2027-01-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of GB491 combined with
Letrozole versus placebo combined with Letrozole in the treatment of HR+/HER2- locally
advanced or metastatic breast cancer without prior systemic antitumor therapy